非小细胞肺癌免疫治疗中超进展疾病定义的澄清
该回顾性队列研究纳入406例接受PD-1/PD-L1抑制剂治疗的晚期NSCLC患者,评估5种HPD定义下HPD发生率及与生存的关联。不同定义下HPD发生率为5.4%至18.5%,定义间一致性33.3%至69.3%,所有定义下HPD均与较差生存相关。ΔTGR>100被确定为区分HPD与普通进展的最佳阈值。
要点
- 不同HPD定义下发生率差异大(5.4%–18.5%),定义间一致性有限。
- 所有HPD定义均与较差总生存相关,中位OS范围3.4–6.0个月。
- ΔTGR>100可能是识别HPD的优化阈值,需更大样本验证。
核心结论
- 既往5种HPD定义并不对应相同的肿瘤行为。
- 基于ΔTGR>100的新定义与HPD预期特征(肿瘤动力学增加和生存差)相关。
- 需更大规模研究确认该定义的准确性和有效性。
研究设计与样本
- 患者均接受PD-1/PD-L1抑制剂单药治疗,可测量病灶依据RECIST 1.1标准在治疗前至少2次和治疗中1次CT扫描定义。
主要发现
- 不同HPD定义下发生率为5.4%(n=22;基于进展速度>2倍且至治疗失败时间<2个月)至18.5%(n=75;基于TGR比值)。
- 不同定义间一致性(Jaccard相似指数)为33.3%至69.3%。
- 每种定义下HPD均与较差生存相关,中位总生存范围3.4个月(95%CI 1.9-8.4)至6.0个月(95%CI 3.7-9.4)。
- 治疗前后TGR差值(ΔTGR)与较差总生存相关性最强,区分HPD与非HPD进展的能力最高。
- ΔTGR>100被确定为区分HPD的最佳阈值。
关键数值与推荐
- HPD发生率范围5.4%至18.5%,取决于所用定义。
- 定义间Jaccard相似指数范围33.3%至69.3%。
- HPD患者中位总生存范围3.4个月(95%CI 1.9-8.4)至6.0个月(95%CI 3.7-9.4)。
- 推荐ΔTGR>100作为HPD的优化定义阈值。
临床怎么用
- 临床识别HPD时应注意不同定义导致发生率差异,建议采用基于ΔTGR>100的统一定义。
- HPD与较差生存相关,需早期识别并考虑调整治疗策略。
- 该定义尚需外部验证,暂不宜直接作为临床决策唯一依据。
局限性
- 回顾性研究设计。
- 样本量有限(406例),需更大规模研究验证。
- 新定义阈值ΔTGR>100的准确性尚未在前瞻性队列中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hyperprogressive disease (HPD) is an aggressive pattern of progression reported for patients treated with programmed cell death 1 (PD-1)/programmed cell death 1 ligand (PD-L1) inhibitors as a single agent in several studies. However, the use of different definitions of HPD introduces the risk of describing different tumoral behaviors. OBJECTIVE: To assess the accuracy of each HPD definition to identify the frequency of HPD and the association with poorer outcomes of immune-checkpoint inhibitor (ICI) treatment in patients with advanced non-small cell lung cancer (NSCLC) and to provide an optimized and homogenized definition based on all previous criteria for identifying HPD. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 406 patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors from November 1, 2012, to April 5, 2017, in 8 French institutions. Measurable lesions were defined using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on at least 2 computed tomographic scans before the initiation of ICI therapy and 1 computed tomographic scan during treatment. Data were analyzed from November 1, 2012, to August 1, 2019. EXPOSURES: Advanced NSCLC and treatment with PD-1/PD-L1 inhibitors. MAIN OUTCOMES AND MEASURES: Association of the definition with the related incidence and the HPD subset constitution and the association between each HPD definition and overall survival. All dynamic indexes used in the previous proposed definitions, such as the tumor growth rate (TGR) or tumor growth kinetics (TGK), were calculated before and during treatment. RESULTS: Among the 406 patients with NSCLC included in the analysis (259 male [63.8%]; median age at start of ICI treatment, 64 [range, 30-91] years), the different definitions resulted in incidences of the HPD phenomenon varying from 5.4% (n = 22; definition based on a progression pace >2-fold and a time to treatment failure of <2 months) to 18.5% (n = 75; definition based on the TGR ratio). The concordance between these different definitions (using the Jaccard similarity index) varied from 33.3% to 69.3%. For every definition, HPD was associated with poorer survival (range of median overall survival, 3.4 [95% CI, 1.9-8.4] to 6.0 [95% CI, 3.7-9.4] months). The difference between TGR before and during therapy (ΔTGR) was the most correlated with poor overall survival with an initial plateau for a larger number of patients and a slower increase, and it had the highest ability to distinguish patients with HPD from those with progressive disease not classified as HPD. In addition, an optimal threshold of ΔTGR of greater than 100 was identified for this distinction. CONCLUSIONS AND RELEVANCE: The findings of this retrospective cohort study of patients with NSCLC suggest that the previous 5 definitions of HPD were not associated with the same tumor behavior. A new definition, based on ΔTGR of greater than 100, appeared to be associated with the characteristics expected with HPD (increase of the tumor kinetics and poor survival). Additional studies on larger groups of patients are necessary to confirm the accuracy and validate this proposed definition.
引用
- Kas B, Talbot H, Ferrara R, et al. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. JAMA Oncol. 2020. PMID: 32525513. doi:10.1001/jamaoncol.2020.1634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。